Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

DELFI Diagnostics has clinically validated FirstLook Lung, its blood test designed to improve early detection of lung cancer, ...

As tariffs, HHS workforce cuts and the ouster of CBER Director Peter Marks threaten the “lifeblood” of the cell and gene ...

The cell and gene therapy company is cutting 47 employees and its entire lupus program to focus resources on two CAR Ts. The ...

As Marty Makary nears the end of his first month on the job, the FDA Commissioner sat down for two interviews, offering ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...